John W. Gillard
Technik-/Wissenschafts-/F&E-Leiter bei Aegera Therapeutics, Inc.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Robert Korneluk | M | - |
Aegera Therapeutics, Inc.
 Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | 24 Jahre |
| Perry B. Molinoff | M | 84 |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | - |
| Alex MacKenzie | M | - |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | 24 Jahre |
| Freda Miller | M | - |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | 24 Jahre |
| Caroline Litchfield | F | 55 | 34 Jahre | |
| Louis P. Lacasse | M | 67 |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | - |
| Trudie Resch | F | - |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | 17 Jahre |
| Joe Regan | M | 56 |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | - |
| Serge Langford | M | - |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | - |
| Inès Holzbaur | M | - |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | - |
| Lennie Ryer | M | 64 |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | - |
| Michael B. Cross | M | 59 |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Richard Kogan | M | 81 | 21 Jahre | |
| Peter Lea | M | - |
Canadian Genetics Diseases Network
 Canadian Genetics Diseases Network Miscellaneous Commercial ServicesCommercial Services Canadian Genetics Diseases Network provides research and development services to the healthcare industry. The company is headquartered in Vancouver, Canada. | 23 Jahre |
| Caroline Dorsa | F | 64 | 22 Jahre | |
| Richard Henriques | M | 68 | 27 Jahre | |
| Kenneth Bartizal | M | 72 | 20 Jahre | |
| Michael H. Thomas | M | 74 |
GLYCODesign, Inc.
 GLYCODesign, Inc. Pharmaceuticals: MajorHealth Technology GLYCODesign, Inc. develops pharmaceutical products. The company engages in the discovery and development of novel therapeutics for life-threatening diseases such as cancer, infectious diseases, inflammation, and cardiovascular diseases. GLYCODesign focuses on inhibiting the enzymes that produce the abnormal carbohydrates. The company was founded by Jeremy Carver in 1993 and is headquartered in Toronto, Canada. | 2 Jahre |
| Marino Carol | F | - | 8 Jahre | |
| John J Horan | M | - | 6 Jahre | |
| Michael Atieh | M | 70 | 19 Jahre | |
| Mark Iwicki | M | 57 | 2 Jahre | |
| Mark Stejbach | M | 61 | 21 Jahre | |
| Ray Hill | M | 79 | 18 Jahre | |
| Romano Robusto | M | - |
Biochem Pharma, Inc.
 Biochem Pharma, Inc. Pharmaceuticals: OtherHealth Technology Biochem Pharma, Inc. provides bioinfomatics tools, biotechnology databases and consulting services to the genomics, proteomics and biopharmaceutical industries. They provide the cutting edge strategic intelligence needed to exploit information and to develop future business strategies. | 8 Jahre |
| Bobby Dwayne Montgomery | M | 56 | 5 Jahre | |
| Elizabeth Stoner | M | 73 | 22 Jahre | |
| Wendy Perrow | F | 66 | 14 Jahre | |
| John Yates | M | 67 | 13 Jahre | |
| Shona McDiarmid | M | - |
Biochem Pharma, Inc.
Biochem Pharma, Inc. Pharmaceuticals: OtherHealth Technology Biochem Pharma, Inc. provides bioinfomatics tools, biotechnology databases and consulting services to the genomics, proteomics and biopharmaceutical industries. They provide the cutting edge strategic intelligence needed to exploit information and to develop future business strategies. | - |
| Danièle Éthier | F | - |
Biochem Pharma, Inc.
Biochem Pharma, Inc. Pharmaceuticals: OtherHealth Technology Biochem Pharma, Inc. provides bioinfomatics tools, biotechnology databases and consulting services to the genomics, proteomics and biopharmaceutical industries. They provide the cutting edge strategic intelligence needed to exploit information and to develop future business strategies. | - |
| Kamil Ali-Jackson | F | 65 | 8 Jahre | |
| Gerald L. Wisler | M | 67 | 20 Jahre | |
| Paul M. Mendelman | M | 76 | 5 Jahre | |
| Gary T. Shearman | M | - | 5 Jahre | |
| Anthony J. Kelly | M | - | - | |
| François Desjardins | M | 61 |
Biochem Pharma, Inc.
Biochem Pharma, Inc. Pharmaceuticals: OtherHealth Technology Biochem Pharma, Inc. provides bioinfomatics tools, biotechnology databases and consulting services to the genomics, proteomics and biopharmaceutical industries. They provide the cutting edge strategic intelligence needed to exploit information and to develop future business strategies. | 6 Jahre |
| John W. Wallen | M | 66 | 6 Jahre | |
| Barry Gilmore | M | - | 14 Jahre | |
| Muna Bhanji | F | 61 | 34 Jahre | |
| Sandy Tremps | F | - | 33 Jahre | |
| Arthur Santora | M | 73 | 28 Jahre | |
| Ron Newbold | M | - | 13 Jahre | |
| Lisa Escudero | F | 62 | 18 Jahre | |
| Jay Galeota | M | 57 | 28 Jahre | |
| Barry Gertz | M | 72 | 28 Jahre | |
| John G. Aunins | M | 63 | 22 Jahre | |
| George McAllister | M | - | 17 Jahre | |
| Oscar Ferenczi | M | 60 | - | |
| Graham Lumsden | M | 64 | 26 Jahre | |
| Scott Anthony Climes | M | 59 | 16 Jahre | |
| Gregory L. Tewalt | M | - | 18 Jahre | |
| Mark C. Twyman | M | 63 | 18 Jahre | |
| Marie-Laure Jeanne Antoinette Pochon | F | 65 | 11 Jahre | |
| Lee Ausburn | F | - | 26 Jahre | |
| Paul Ronald Bell | M | 76 | 14 Jahre | |
| Horace D. Nalle | M | - | - | |
| Richard Gauthier | M | - |
Biochem Pharma, Inc.
Biochem Pharma, Inc. Pharmaceuticals: OtherHealth Technology Biochem Pharma, Inc. provides bioinfomatics tools, biotechnology databases and consulting services to the genomics, proteomics and biopharmaceutical industries. They provide the cutting edge strategic intelligence needed to exploit information and to develop future business strategies. | 5 Jahre |
| Ed M. Scolnick | M | 83 | 20 Jahre | |
| Philippe Schaison | M | 62 | 7 Jahre | |
| Myrtle Potter | F | 65 | 14 Jahre | |
| Jerome C. Keller | M | 81 | 7 Jahre | |
| Robert F. Hendrickson | M | 91 | 5 Jahre | |
| Abraham E. Cohen | M | 87 | 10 Jahre | |
| John L. Zabriskie | M | 85 | 6 Jahre | |
| Judy Lewent | F | 75 | 27 Jahre | |
| William G. Bowen | M | 90 | 21 Jahre | |
| Timothy Proctor | M | 74 | 13 Jahre | |
| R. Gordon Douglas | M | 89 | 8 Jahre | |
| Adam Schechter | M | 59 | 30 Jahre | |
| Stefan Oschmann | M | 67 | 20 Jahre | |
| Nolan Sigal | M | 73 | 10 Jahre | |
| Ronald Newbold | M | 61 | 9 Jahre | |
| James Tananbaum | M | 60 | 2 Jahre | |
| Bradley Sheares | M | 67 | 19 Jahre | |
| Elizabeth Hamilton Seabury Wyatt | M | 76 | 20 Jahre | |
| Kevin P. Brady | M | 68 | 6 Jahre | |
| Stewart John Hen | M | 57 | 4 Jahre | |
| Michael R. Goldberg | M | - | 17 Jahre | |
| Jean-Michael Halfon | M | 72 | 2 Jahre | |
| George Morrow | M | 72 | 11 Jahre | |
| Michael Rosenblatt | M | 76 | 32 Jahre | |
| Martial Lacroix | M | - |
Biochem Pharma, Inc.
Biochem Pharma, Inc. Pharmaceuticals: OtherHealth Technology Biochem Pharma, Inc. provides bioinfomatics tools, biotechnology databases and consulting services to the genomics, proteomics and biopharmaceutical industries. They provide the cutting edge strategic intelligence needed to exploit information and to develop future business strategies. | 2 Jahre |
| Michael L. Corrado | M | 75 | 7 Jahre | |
| Mario Thomas | M | 73 |
Biochem Pharma, Inc.
Biochem Pharma, Inc. Pharmaceuticals: OtherHealth Technology Biochem Pharma, Inc. provides bioinfomatics tools, biotechnology databases and consulting services to the genomics, proteomics and biopharmaceutical industries. They provide the cutting edge strategic intelligence needed to exploit information and to develop future business strategies. | - |
| Susan Molineaux | M | 70 | 5 Jahre | |
| Gregory S. Patrick | M | 72 | 14 Jahre | |
| André Archimbaud | M | - |
Kinetek Pharmaceuticals, Inc.
| 6 Jahre |
| Robert G. Johnson | M | 72 | 7 Jahre | |
| Guy MacDonald | M | 65 | 22 Jahre | |
| Ben Shapiro | M | 84 | 13 Jahre | |
| Christine Lennon | F | - |
Biochem Pharma, Inc.
Biochem Pharma, Inc. Pharmaceuticals: OtherHealth Technology Biochem Pharma, Inc. provides bioinfomatics tools, biotechnology databases and consulting services to the genomics, proteomics and biopharmaceutical industries. They provide the cutting edge strategic intelligence needed to exploit information and to develop future business strategies. | - |
| Kenneth R. Nover | M | - | 13 Jahre | |
| Julian Adams | M | 69 | 5 Jahre | |
| Kathryn E. Giusti | F | 65 | 3 Jahre | |
| Buck Newsome | M | 67 | 4 Jahre | |
| Gerald McLaughlin | M | 56 | 11 Jahre | |
| Christine Cioffe | F | - | 20 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 76 | 77,55% |
| Kanada | 22 | 22,45% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- John W. Gillard
- Persönliches Netzwerk
